publication venue for
- Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer.. 43:1211-1221. 2025
- Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?. 35:386-391. 2017